No Data
Cathie Wood's Top and Bottom Performing ARKK Holdings of H1
Natera's New Cancer Trial to Use Signatera for Personalized Treatment
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced a new gastroesophageal cancer trial, DECIPHER, that will utilize the company's personalized an
Express News | Natera Announces Decipher: A Phase II, Single-Arm Adjuvant Trial in Gastroesophageal Cancer
Natera(NTRA.US) Director Sells US$296.08K in Common Stock
$Natera(NTRA.US)$ Director Sheena Jonathan sold 2,700 shares of common stock on Jun 18, 2024 at an average price of $109.6591 for a total value of $296.08K.Source: Announcement What is statement of ch
$100 Invested In Natera 5 Years Ago Would Be Worth This Much Today
Natera (NASDAQ:NTRA) has outperformed the market over the past 5 years by 19.2% on an annualized basis producing an average annual return of 32.67%. Currently, Natera has a market capitalization of $1
Health Check: How Prudently Does Natera (NASDAQ:NTRA) Use Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor